Sodium-glucose co-transporter-2 (SGLT2) inhibitors are well-recognised antidiabetic medications among clinicians due to its highly protective effects on cardiovascular and renal systems diabetic patients. However, one of uncommonly reported side is the development euglycemic ketoacidosis (EuDKA) which characterized by mild hyperglycemia, ketosis acidosis. Chest pain as a clinical present...

Abstract Introduction Atrial fibrillation (AF), the most common cardiac arrhythmia, is associated with increased morbidity and mortality. Inflammatory infiltrates have been observed in atrial tissues from AF patients suggesting that low-grade inflammation contributes to pro-fibrotic, pro-remodeling pro-senescence responses of tissue favoring AF. Although sodium glucose co-transporter2 inhibitor...

Abstract Background Hyperactivity of the sympathetic nervous system (SNS) promotes cardiac dysfunction, that can contribute to heart failure and even cardiogenic shock. Endothelial dysfunction associated with increased formation reactive oxygen species (ROS) has been suggested promote failure. Our previous results showed SGLT2 ROS derived from endothelial NADPH oxidases dysfunction. Purpose The...

The Na-glucose cotransporter SGLT2 mediates high-capacity glucose uptake in the early proximal tubule and SGLT2 inhibitors are developed as new antidiabetic drugs. We used gene-targeted Sglt2 knockout (Sglt2(-/-)) mice to elucidate the contribution of SGLT2 to blood glucose control, glomerular hyperfiltration, kidney growth, and markers of renal growth and injury at 5 wk and 4.5 mo after induct...

The Renal sodium-dependent glucose co-transporter 2 (SGLT2) is one of the most promising targets for the treatment of type 2 diabetes. Two SGLT2 inhibitors, dapagliflozin, and canagliflozin, have already been approved for use in USA and Europe; several additional compounds are also being developed for this purpose. Based on the in vitro IC50 values and plasma concentration of dapagliflozin meas...

Sodium-glucose cotransporter-2 (SGLT2) inhibitors have become increasingly prescribed because of their proven protective effects on the heart and kidneys, carbohydrate-restricted diets are popular therapeutic approaches for patients with obesity diabetes. A 28-year-old obese woman recently diagnosed diabetes developed euglycemic diabetic ketoacidosis (DKA) while dapagliflozin, an SGLT2 inhibito...

PURPOSE OF REVIEW Reabsorption of glucose in the proximal tubule occurs predominantly via the sodium glucose cotransporter 2 (SGLT2). There has been intense interest in this transporter as a number of SGLT2 inhibitors have entered clinical development. SGLT2 inhibitors act to lower plasma glucose by promoting glycosuria and this review aims to outline the effect on the diabetic kidney of this h...